Chemiluminescence Immunoassay (CLIA) Analyzers Market: Information by Type (High Throughput, Medium Throughput and Low Throughput) Product (Reagents, Analyzer and Consumables), Application (Oncology & Endocrinology, Hepatitis and Retroviruses, Cardiac Markers, Infectious Disease, Bone and Mineral Disorders, Auto-Immune Diseases, Allergy, GI Stool Testing, Drug Discovery and Development), End User (Hospitals & Clinics, Medical & Diagnostic Laboratories, Pharmaceutical Companies) - Forecast till 2027

Chemiluminescence Immunoassay (CLIA) Analyzers Market Overview

The Chemiluminescence Immunoassay (CLIA) Analyzers Market is anticipated to reach USD 12.35 billion by 2030 at 7.3% CAGR during the forecast period 2022-2030

chemiluminescence immunoassay analyzer is mainly used in monitoring and detecting any chronic diseases. Physicians also take great help from this instrument by collecting information about the disease and treat it. Several inherited genetic diseases can be diagnosed with the presence of chemiluminescence immunoassay analyzer. It helps the physician to understand the diagnosis, prognosis, pathogenesis and ethology which further help in a better and personalised treatment.

Chemiluminescence Immunoassay (CLIA) Analyzers Market dynamics

Drivers

Rapid changes in eating habits and lifestyle is the reason behind the increasing rate of chronic diseases such as cancer. Therefore, the increasing prevalence of acute and chronic diseases are the driving factors behind the growth of the market.

Challenges

Although the market has a high potential of growth during the forecast period, it has also some challenging factors as well. The lack of skilled labours or trained professionals in the healthcare segment is expected to hinder the growth of the market.

Restrains

The stringent regulatory policies are going to be the restraining factor in the growth of the chemiluminescence immunoassay analyzer market.

Opportunities

The high specificity and technological advancements are creating several opportunities for the chemiluminescence immunoassay analyzer manufacturers in the market. The rising demands are also going to create opportunities for the analyzers laboratory immunoassay chemiluminescence.

Chemiluminescence Immunoassay (CLIA) Analyzers Market Segmentation overview

The global Chemiluminescence Immunoassay (CLIA) Analyzers Market is segmented into-

• Type


• Product


• Application


• End-User


• Region

By Type

Based on type, the Chemiluminescence Immunoassay (CLIA) Analyzers Market is further segmented into-

• High Throughput


• Medium Throughput


• Low Throughput

By Product

Based on type, the Chemiluminescence Immunoassay (CLIA) Analyzers Market is further segmented into-

• 
  Reagents
  
  
  
  • Enzymatic Markers
  
  
  • Luminophore Markers
  
  
  
  


• 
  Analyzer
  
  
  
  • Automated
  
  
  • Semi-automated
  
  
  
  


• Consumables

By Application

Based on type, the Chemiluminescence Immunoassay (CLIA) Analyzers Market is further segmented into-

• Oncology & Endocrinology


• Hepatitis and Retroviruses


• Cardiac Markers


• Infectious Disease


• Bone and Mineral Disorders


• Auto-Immune Diseases


• Allergy


• GI Stool Testing


• Drug Discovery and Development


• Others

By End-User

Based on end-user, the Chemiluminescence Immunoassay (CLIA) Analyzers Market is further segmented into

• Hospitals & Clinics


• Medical & Diagnostic Laboratories


• Pharmaceutical & Biotechnology Industries


• Others

By Region

Based on region, the Chemiluminescence Immunoassay (CLIA) Analyzers Market is further segmented into

• 
  Americas
  
  
  
  • 
    North America
    
    
    
    • US
    
    
    • Canada
    
    
    • Latin America
    
    
    
    
  
  
  
  


• 
  Europe
  
  
  
  • 
    Western Europe
    
    
    
    • Germany
    
    
    • UK
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Regional analysis

The Americas is expected to be the leading Chemiluminescence Immunoassay (CLIA) Analyzers Market due to the increasing prevalence of chronic diseases such as cancer. The National Cancer Institute stated that 1,688,780 new cases of cancer were estimated in 2017 in the US alone. Therefore, the increasing number of patients will help the market to grow during the forecast period. The rising research and development costs incurred by healthcare institutions and government bodies are also a key factor contributing to the Chemiluminescence Immunoassay (CLIA) Analyzers Market growth.

Europe is forecast to be the second-largest Chemiluminescence Immunoassay (CLIA) Analyzers Market. The European market has been further segregated into Western Europe and Eastern Europe. Western Europe includes Germany, the UK, Italy, Spain, France, and other countries in western Europe. The Eastern European region consists of countries such as Russia, Poland, Romania and other countries in eastern Europe. Europe held a healthy share in the CLIA analyzers market and is the second-largest market leader after the Americas. Rising government initiatives to promote research in chronic diseases, high healthcare expenditure, and high accessibility to advanced treatment facilities are some of the factors driving growth of this market.

Asia-Pacific is anticipated to grow at the fastest rate during the forecast period due to increasing government initiatives for healthcare reform, a large patient pool suffering from chronic diseases, and huge capital investment. However, less awareness regarding healthcare IT and less capital investment are some of the factors challenging market growth in this region.

Recent developments

June 2020-  Abbott announced that it is supplying its laboratory-based serology blood test for the detection of COVID-19 antibody. This means that ICMR’s strategy of using IgG CLIA antibody tests will be contributed to by this test.

July 2018- DiaSorin receives clearance from the CE Notified Body to market the LIAISON® XL Murex Anti-HDV assay for the diagnosis of Hepatitis D virus (HDV) infection. The company’s CLIA menu for hepatitis testing now includes a test to diagnose HDV, which is usually found in patients with chronic liver disease.

January 2018- DiaSorin S.p.A. partnered with QIAGEN N.V., a molecular diagnostics company, to add the latter’s QuantiFERON-TB (QFT) diagnostic test to the former’s LIAISON family of fully automated analyzers for infectious disease testing in hospital laboratories.

Major key players

There are many prominent key players present in the market. Among all the key players investing in the market, here is the list of most prominent ones-

• Abbott


• Hoffmann-La Roche Ltd


• Siemens Healthcare GmbH (Siemens AG)


• Danaher (Beckman Coulter, Inc.)


• DiaSorin S.p.A.


• Ortho Clinical Diagnostics (Part of Carlyle Group)


• Shenzhen New Industries Biomedical Engineering Co., Ltd.


• Sysmex Corporation


• Randox Laboratories Ltd.


• Tosoh Corporation


• Others

Report Overview

The report comprises of

• Market overview


• Covid-19 impact


• Market dynamics


• Drivers


• Challenges


• Restrains


• Opportunities


• Technological analysis


• Segmentation overview


• Regional analysis


• Competitive landscape


• Recent developments


• Major key players